Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
2022 · Nature Medicine · 325 citations
https://doi.org/10.1038/s41591-022-01829-9
J
Jaclyn P. Lyman
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
27
Papers
1.1K
Citations
9
h-index
8
i10-index
Jaclyn P. Lyman is an academic researcher from Lustgarten Foundation. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Pancreatic and Hepatic Oncology Research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 9, co-authored 23 publications.
Papers by this author
worksPrognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013
2016 · Journal of Clinical Oncology · 82 citations
https://doi.org/10.1200/jco.2015.63.1960
343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer
2021 · Regular and Young Investigator Award Abstracts · 1 citations
https://doi.org/10.1136/jitc-2021-sitc2021.343
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat